Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Infectious Disease Research Institute · University of Washington · +3 more institutions
Abstract
Cells per kg) had a higher infection density within 28 days in an adjusted model of baseline characteristics. Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis. The incidence of infections was comparable to observations from clinical trials of salvage chemoimmunotherapies in similar patients. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
Citation impact
- FWCI
- 15.01
- Percentile
- 100%
- References
- 30
Authors
10- JAJoshua A. HillCorresponding
Infectious Disease Research Institute, University of Washington, Fred Hutch Cancer Center, Cancer Research Center
- DLDaniel Li
- KAKevin A. Hay
University of British Columbia, Fred Hutch Cancer Center
- MLMargaret L. Green
Infectious Disease Research Institute, University of Washington, Fred Hutch Cancer Center, Cancer Research Center
- SCSindhu Cherian
University of Washington
Topics & keywords
- Chimeric antigen receptor
- Immunotherapy
- Medicine
- CD19
- Antigen
- Immunology
- Virology
- Cancer research
- Good health and well-being